Michael Ackermann (Allergan) - A Tearful Tale of Biodesign

from Entrepreneurial Thought Leaders (ETL)

Michael Ackermann, CEO of a med-tech startup that created a tear-stimulation device for those with dry-eye disease, explains how acquisition by a global pharmaceutical giant is helping him achieve his goal of reaching as many patients as possible. Ackermann, a graduate of the Stanford Byers Center for Biodesign, also discusses why big tech companies have yet to disrupt healthcare and how that translates into big opportunities for entrepreneurs.

Episode metadata supplied by the publisher feed · Published Nov 16, 2016

Embed this episode

Attribution link and audio player

NOW PLAYING

Michael Ackermann (Allergan) - A Tearful Tale of Biodesign

0:00 56:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Entrepreneurial Thought Leaders (ETL)?

This episode is 56 minutes long.

When was this Entrepreneurial Thought Leaders (ETL) episode published?

This episode was published on November 16, 2016.

Can I download this Entrepreneurial Thought Leaders (ETL) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!